Beamion Lung 1, an ongoing phase Ia/Ib trial of the HER2 TKI, BI 1810631 in patients (pts) with advanced solid tumors with HER2 aberrations: Latest data

被引：2
|
作者：
Opdam, F. [1 ]
Heymach, J. [2 ]
Ruiter, G. [3 ]
Barve, M. [4 ]
Tu, H. [5 ]
Wu, Y-L. [5 ]
Schroeter, L. [6 ]
Sadrolhefazi, B. [7 ]
Serra, J. [8 ]
Yoh, K. [9 ]
Yamamoto, N. [10 ]
机构：
[1] Netherlands Canc Inst, Dept Clin Pharmacol, Amsterdam, Netherlands
[2] Univ Texas Houston, Div Canc Med, Dept Thorac Head & Neck Med Oncol, MD Anderson Canc Ctr, Houston, TX USA
[3] Netherlands Canc Inst, Antoni van Leeuwenhoek Hosp, Thorac Oncol & Phase 1 Studies, NKI AVL, Amsterdam, Netherlands
[4] Mary Crowley Canc Res Ctr, Dallas, TX USA
[5] Southern Med Univ, Guangdong Lung Canc Inst, Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Guangzhou, Peoples R China
[6] Boehringer Ingelheim Pharma GmbH & Co KG, Biostat & Data Sci, Biberach, Germany
[7] Boehringer Ingelheim Pharmaceut Inc, Oncol, Ridgefield, CT USA
[8] Boehringer Ingelheim SA, CD&O, Sant Cugat Del Valles, Spain
[9] Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, Chiba, Japan
[10] Natl Canc Ctr, Dept Thorac Oncol, Tokyo, Japan
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2408
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1375P
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Beamion Lung 1, a Phase Ia/Ib Trial of the HER2 TKI, BI 1810631 in Patients with Advanced Solid Tumors with HER2 Aberrations
    Yamamoto, N.
    Opdam, F.
    Barve, M.
    Tu, H. -Y.
    Wu, Y. -L.
    Schroeter, L.
    Sadrolhefazi, B.
    Serra, J.
    Yoh, K.
    Heymach, J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S147 - S147
  • [2] Updated data from the phase I Beamion Lung 1 trial of BI 1810631, a HER2 TKI, in patients (pts) with advanced solid tumours with HER2 aberrations
    Opdam, F.
    Heymach, J.
    Barve, M.
    Tu, H-Y.
    Wu, Y-L.
    Gibson, N. J.
    Sadrolhefazi, B.
    Serra, J.
    Yoh, K.
    Yamamoto, N.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S63 - S64
  • [3] Phase I Beamion Lung 1 trial of BI 1810631, a HER2 tyrosine kinase inhibitor (TKI), as monotherapy in patients (pts) with advanced/metastatic solid tumors with HER2 aberrations: Updated data.
    Heymach, John
    Opdam, Frans
    Barve, Minal A.
    Tu, Hai-Yan
    Wu, Yi-Long
    Berz, David
    Gibson, Neil
    Sadrolhefazi, Behbood
    Serra, Josep
    Yoh, Kiyotaka
    Yamamoto, Noboru
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] Updated data from the Phase I Beamion Lung 1 trial of the HER2 tyrosine kinase inhibitor (TKI), BI 1810631, as monotherapy in patients (pts) with advanced/metastatic solid tumors with HER2 aberrations
    Heymach, John
    Opdam, Frans
    Barve, Minal
    Tu, Hai-Yan
    Wu, Yi-Long
    Gibson, Neil
    Sadrolhefazi, Behbood
    Serra, Josep
    Yoh, Kiyotaka
    Yamamoto, Noboru
    CANCER RESEARCH, 2023, 83 (08)
  • [5] A Phase I trial of BI 1810631, a HER2 tyrosine kinase inhibitor (TKI), as monotherapy in patients (pts) with advanced/metastatic solid tumors with HER2 aberrations
    Opdam, F.
    Heymach, J.
    Barve, M.
    Wu, Y. L.
    Gibson, N.
    Sadrolhefazi, B.
    Serra, J.
    Yoh, K.
    Yamamoto, N.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S1 - S1
  • [6] A Phase I Trial of the HER2 Exon 20 Inhibitor, BI 1810631, In Patients With Advanced Solid Tumors With HER2 Aberrations
    Opdam, F.
    Heymach, J.
    Barve, M.
    Gibson, N.
    Sadrolhefazi, B.
    Serra, J.
    Yamamoto, N.
    Yoh, K.
    Wu, Y. -L.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S421 - S422
  • [7] Beamion LUNG-1: Phase Ia/b Trial of HER2 Tyrosine Kinase Inhibitor Zongertinib (BI 1810631) in Patients with HER2 Aberration-Positive Solid Tumors
    Heymach, John
    Yamamoto, Noboru
    Opdam, Frans
    Barve, Minal
    Tu, Hai-Yan
    Wu, Yi-Long
    Schroeter, Lukas
    Sadrolhefazi, Behbood
    Serra, Josep
    Yoh, Kiyotaka
    Berz, David
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E1 - E1
  • [8] Phase Ia/Ib trial of zongertinib (BI 1810631), a HER2-specific tyrosine kinase inhibitor (TKI), in patients (pts) with HER2 aberration-positive solid tumors: Updated Phase Ia data from Beamion LUNG-1, including progression-free survival (PFS) data
    Heymach, John
    Opdam, Frans
    Barve, Minal A.
    Tu, Hai-Yan
    Wu, Yi-Long
    Berz, David
    Rohrbacher, Maren
    Sadrolhefazi, Behbood
    Serra, Josep
    Yoh, Kiyotaka
    Yamamoto, Noboru
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [9] Beamion LUNG-1, a Phase Ia/Ib trial of the HER2-specific tyrosine kinase inhibitor, zongertinib (BI 1810631), in patients with HER2-driven tumors: outcomes according to HER2 aberration type
    Berz, D.
    Heymach, J.
    Opdam, F.
    Barve, M.
    Tu, H.
    Wu, Y.
    Mueller, A. M.
    Schroeter, L.
    Sadrolhefazi, B.
    Yoh, K.
    Yamamoto, N.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2024, 162 : S127 - S127
  • [10] Phase Ia/Ib trial of the HER2 tyrosine kinase inhibitor zongertinib (BI 1810631) in patients with HER2-driven solid tumors: Focus on Asian patients
    Yoh, K.
    Opdam, F.
    Barve, M.
    Tu, H.
    Wu, Y-L.
    Berz, D.
    Schroeter, L.
    Sadrolhefazi, B.
    Serra, J.
    Heymach, J.
    Yamamoto, N.
    ANNALS OF ONCOLOGY, 2024, 35 : S1637 - S1638
12345